The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Several mechanisms and cell types are involved in the regulation of the immune response.
These include mostly regulatory T cells (Tregs), regulatory macrophages (Mregs), myeloid …

Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

The role and importance of neutrophils in cancer has become increasingly apparent over
the past decade. Neutrophils accumulate in the peripheral blood of patients with cancer …

Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma
treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived …

Under steady-state conditions, bone marrow-derived immature myeloid cells (IMC)
differentiate into granulocytes, macrophages and dendritic cells (DCs). This differentiation is …

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells
generated during a large array of pathologic conditions ranging from cancer to obesity …

The biological functions and mechanisms of oncogenic KRAS G12D (KRAS∗) in resistance
to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that …